Nunzia Pharmaceutical logo

Nunzia Pharmaceutical(OTC) NUNZ

Market Cap$43.50KMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (1995)-100%
5 Year-100%
1 Year+9,900%
1 Month+0%
$0.00
+0.00%
+0.00Today
Nunzia Pharmaceutical last closing stock price
MetricPriceDate
Last closeUSD 0.002026-06-05
Nunzia Pharmaceutical stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+0%USD 0.002026-05-04
1 month+0%USD 0.002026-05-04
3 month+0%USD 0.002026-01-30
Year to date+0%USD 0.002025-12-24
1 year+9,900%USD 0.002025-03-05
3 year-99.8%USD 0.052023-06-06
5 year-99.99%USD 1.732021-05-28
Since inception-100%USD 5,252,100.841995-02-27

Nunzia Pharmaceutical Financials at a Glance

Market Cap

$43.50KMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$0.00

Net Income (TTM)

-$96.99M

EPS (TTM)

$0.00

P/E Ratio

0.00

Dividend

$0.00

Beta (Volatility)

0.44 (Low)

Price

$0.00

Volume

1

Open

$0.00

Previous Close

$0.00

Daily Range

$0.00 - $0.00

52-Week Range

$0.00 - $0.00

Estimated Earnings Date

N/A

NUNZ News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Nunzia Pharmaceutical

Nunzia Pharmaceutical Company operates as a pharmaceutical and nutraceutical company focused on developing treatments for various disorders, including autism and ADHD. The company is based in Long Beach, California, and offers its products through wholesalers and its website.

Products and Services
  • Manufactures and distributes nutraceuticals targeting autism, ADHD, and PTSD
  • Offers products through wholesalers and direct online sales
  • Focuses on innovative solutions in the healthcare sector
Growth Outlook
  • Potential market expansion in the growing nutraceutical sector
  • Increased awareness of mental health disorders driving demand
  • Strategic partnerships could enhance product distribution
Financial Highlights
  • Recent quarterly net income of -$245,403, reflecting ongoing operational challenges
  • Trailing twelve months (TTM) revenue remains at $0, indicating early-stage development
  • Cash and cash equivalents of $30,373 as of September 30, 2022, providing liquidity
Nunzia Pharmaceutical Company is positioned in a niche market with significant growth potential. The focus on nutraceuticals for mental health disorders aligns with increasing consumer awareness and demand. Despite current financial challenges, the company maintains a strategic outlook for future growth through potential market expansion and partnerships. Investors may find interest in the company's innovative approach to addressing critical health issues.
AI Generated • Oct 1, 2026

Industry

Personal Products

CEO

Charles A. Strongo, MBA

Headquarters

Long Beach, CA 90813, US

NUNZ Financials

Key Financial Metrics (TTM)

Gross Margin

0.00%

Operating Margin

0.00%

Net Income Margin

0.00%

Return on Equity

101661.22%

Return on Capital

-2387913.98%

Return on Assets

-1521431.14%

Earnings Yield

N/A

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$43.50KMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

434.51M

Volume

1

Avg. Volume

0

Financials (TTM)

Gross Profit

$0.00

Operating Income

-$96.97M

EBITDA

-$96.80M

Operating Cash Flow

-$277.92K

Capital Expenditure

$0.00

Free Cash Flow

-$277.92K

Cash & ST Invst.

$35.37K

Total Debt

$183.35K

Nunzia Pharmaceutical Performance Analysis

Nunzia Pharmaceutical annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20212021-12-31USD 0N/A
Nunzia Pharmaceutical sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q42021-12-31N/A
Q12022-03-31N/A
Q22022-06-30N/A
Q32022-09-30N/A
Nunzia Pharmaceutical annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20212021-12-31USD -0.26N/A
Nunzia Pharmaceutical sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q42021-12-31-269900.0%
Q12022-03-3184.0%
Q22022-06-3099.9%
Q32022-09-30-1196.1%

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Currently no data to display.

Quarterly Performance

Name
Q3 2022YOY CHG

Revenue

$0.00

N/A

Gross Profit

$0.00

N/A

Gross Margin

0.00%

N/A

Market Cap

$43.50KMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$10.88K

N/A

Employees

4

N/A

Net Income

-$245.40K

-610.8%

EBITDA

-$200.35K

-480.3%

Quarterly Fundamentals

Name
Q3 2022YOY CHG

Total Cash

$35.37K

+7223.6%

Total Debt

$183.35K

+697.2%

Accounts Receivable

$0.00

N/A

Inventory

$0.00

N/A

Long Term Debt

$0.00

N/A

Short Term Debt

$183.35K

N/A

Return on Assets

-15214.31%

N/A

Return on Invested Capital

828.90%

N/A

Free Cash Flow

-$113.09K

-10987.1%

Operating Cash Flow

-$113.09K

-10987.1%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
AKANAkanda Corp.
$1.93+2.12%
CSUICannabis Suisse Corp.
$0.01+0.00%
IMCCIM Cannabis Corp.
$1.90-2.06%
RDHLRedHill Biopharma Ltd.
$0.47-2.07%

Trending Stocks

Symbol / CompanyPricePrice Chg
INTCIntel
$113.12+0.55%
NUNu Holdings
$15.58-0.51%
NVDANvidia
$237.47-0.74%
BULLWebull
$5.89-19.09%

Questions About NUNZ

What is the current price of Nunzia Pharmaceutical?

Nunzia Pharmaceutical is trading at $0.00 per share.

What is the 52-week range for Nunzia Pharmaceutical?

Over the past 52 weeks, Nunzia Pharmaceutical has traded between $0.00 and $0.00.

How much debt does Nunzia Pharmaceutical have?

As of the most recent reporting period, Nunzia Pharmaceutical reported total debt of $0.00.

How much cash does Nunzia Pharmaceutical have on hand?

Nunzia Pharmaceutical reported $131.00 in cash and cash equivalents in its most recent financial results.

What is Nunzia Pharmaceutical’s dividend yield?

Nunzia Pharmaceutical does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.